PubRank

H Lode

Author PubWeight™ 130.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985 4.07
2 [Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)]. Infection 1977 2.54
3 Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother 1979 2.23
4 Clinical evaluation of a Mycobacterium tuberculosis PCR assay. J Clin Microbiol 1995 2.19
5 Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996 2.18
6 Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol 1986 2.00
7 Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998 1.95
8 Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol 1985 1.86
9 Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000 1.80
10 Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993. Eur Respir J 1995 1.52
11 Increased number of alveolar macrophages expressing adhesion molecules of the leukocyte adhesion molecule family in smoking subjects. Association with cell-binding ability and superoxide anion production. Am Rev Respir Dis 1992 1.49
12 Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther 1980 1.46
13 [Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance]. Dtsch Med Wochenschr 2008 1.45
14 Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J Clin Virol 2004 1.39
15 Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother 1983 1.39
16 Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J 2006 1.29
17 Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother 1984 1.28
18 Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J 2006 1.28
19 Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000 1.27
20 [Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother 1975 1.26
21 Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003 1.24
22 Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother 1999 1.24
23 Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother 1982 1.19
24 Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 1996 1.19
25 Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis 1992 1.17
26 Determination of cefmenoxime in human body fluids by high-performance liquid chromatography. Eur J Clin Microbiol 1983 1.08
27 Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother 1983 1.07
28 Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med 1997 1.05
29 Amplification of Mycobacterium tuberculosis from peripheral blood. J Clin Microbiol 1995 1.03
30 Toxicity of quinolones. Drugs 1999 1.03
31 Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother 1983 1.03
32 Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother 1992 1.02
33 Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 1996 1.01
34 Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1989 1.00
35 Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992 1.00
36 Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother 1983 0.99
37 Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr 1979 0.99
38 Lymphocyte subsets in peripheral blood and smoking habits. Lung 1997 0.98
39 Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study. J Antimicrob Chemother 1980 0.98
40 Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother 1988 0.97
41 Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. Eur Respir J 1995 0.97
42 Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. J Clin Chem Clin Biochem 1986 0.97
43 Meropenem: clinical response in relation to in vitro susceptibility. Clin Microbiol Infect 2000 0.96
44 Determination of sparfloxacin in serum and urine by high-performance liquid chromatography. J Chromatogr 1992 0.96
45 Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999 0.96
46 Cells and cytokines in chronic bronchial infection. Ann N Y Acad Sci 1994 0.96
47 Reduced spontaneous apoptosis in peripheral blood neutrophils during exacerbation of COPD. Eur Respir J 2004 0.96
48 Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis 1976 0.94
49 Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir Med 2004 0.93
50 Determination of linezolid in human serum and urine by high-performance liquid chromatography. Int J Antimicrob Agents 2001 0.92
51 Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother 1994 0.92
52 Fluoroquinolones: interaction profile during enteral absorption. Drugs 1993 0.91
53 Significance of non-pneumophila Legionella species in adult community-acquired and nosocomial pneumonias. Klin Wochenschr 1987 0.91
54 HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. Clin Infect Dis 2005 0.91
55 Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 2005 0.90
56 Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study. Infection 2006 0.89
57 Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother 1997 0.88
58 [Comparative pharmacokinetics of oral cephalosporins: cephalexin, cefaclor and cefadroxil (author's transl)]. Arzneimittelforschung 1980 0.88
59 Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling. Crit Care 2001 0.88
60 Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 2000 0.87
61 Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother 1990 0.87
62 Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs 1988 0.87
63 Superoxide anion release induced by platelet-activating factor is increased in human alveolar macrophages from smokers. Eur Respir J 1992 0.87
64 Determination of trovafloxacin in human body fluids by high-performance liquid chromatography. J Chromatogr A 1999 0.87
65 Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit 1987 0.87
66 Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J 1997 0.86
67 Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet 1985 0.86
68 Pharmacokinetics of FCE 22891, a new oral penem. Antimicrob Agents Chemother 1990 0.86
69 Pneumococcal vaccination. Eur Respir J 2005 0.86
70 [A Q fever epidemic in Berlin. The epidemiological and clinical aspects]. Dtsch Med Wochenschr 1993 0.86
71 Comparative clinical pharmacology of three ampicillins and amoxicillin administered orally. J Infect Dis 1974 0.86
72 Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis 1993 0.86
73 [Diagnosis and antibiotic treatment of infectious diseases in general practice. Results of an inquiry]. Dtsch Med Wochenschr 1983 0.86
74 [Combination therapy using penicillin. Methods of analysis and pharmacokinetics of oxacillin and ampicillin administered simultaneously]. Arzneimittelforschung 1973 0.85
75 Increased number of alveolar macrophages expressing surface molecules of the CD11/CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cells. Am Rev Respir Dis 1993 0.85
76 Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrob Agents Chemother 1993 0.85
77 Penetration of antibiotics into the pleural fluid. J Antimicrob Chemother 1979 0.83
78 Interleukin-10: effects on phagocytosis and adhesion molecule expression of granulocytes and monocytes in a comparison with prednisolone. Eur J Med Res 1999 0.83
79 Significance of pleural and sputum concentrations for antibiotic therapy of bronchopulmonary infections. Infection 1980 0.83
80 Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy 1985 0.83
81 Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis 2005 0.82
82 [Septicemia. Etiology, epidemiology, clinical aspects and prognosis in 446 patients]. Dtsch Med Wochenschr 1983 0.82
83 [Pharmacokinetic comparative studies on the resorption of 3 new cephalosporins]. Verh Dtsch Ges Inn Med 1978 0.82
84 Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004 0.82
85 Antibiotic infection prophylaxis in gallbladder surgery--a prospective randomized study. Chemotherapy 1985 0.81
86 Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother 1996 0.81
87 Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver. Chemotherapy 1984 0.81
88 [Inactivation of antibiotics in infusion solutions]. Infection 1973 0.81
89 Supplementary dose after hemodialysis. Nephron 1982 0.81
90 Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. Antimicrob Agents Chemother 2000 0.81
91 Subpopulations of alveolar macrophages in smokers and nonsmokers: relation to the expression of CD11/CD18 molecules and superoxide anion production. Am J Respir Crit Care Med 1995 0.81
92 Pharmacokinetics of cefadroxil and cefaclor during an eight-day dosage period. Antimicrob Agents Chemother 1982 0.81
93 [Changes in pulmonary function of young adults as a result of long time cigarette smoking]. Dtsch Med Wochenschr 1971 0.81
94 Combination therapy with beta-lactam antibiotics. J Antimicrob Chemother 1983 0.81
95 Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995 0.81
96 Endothelin increases [Ca2+]i, protein phosphorylation, and O2-. production in human alveolar macrophages. Am J Physiol 1991 0.81
97 [Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy]. Med Monatsschr Pharm 2002 0.81
98 Pharmacokinetics of temocillin in volunteers. Drugs 1985 0.81
99 Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008 0.80
100 The pharmacokinetics of ticarcillin, clavulanic acid and their combination. J Antimicrob Chemother 1986 0.80
101 [Infectious endocarditis: clinical findings, therapy and course in 103 patients]. Dtsch Med Wochenschr 1982 0.80
102 Pharmacokinetics and serum bactericidal activity of ticarcillin and clavulanic acid. J Antimicrob Chemother 1985 0.80
103 Pharmacokinetics of multiple doses of ceftizoxime and their influence on fecal flora. Eur J Clin Microbiol 1983 0.80
104 Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. Eur J Clin Microbiol Infect Dis 2000 0.79
105 Evidence for a platelet-activating factor receptor on human alveolar macrophages. Biochem Biophys Res Commun 1991 0.79
106 [Is monotherapy with β-lactam antibiotics still up to date? New aspects for treatment of severe infections]. Dtsch Med Wochenschr 2012 0.79
107 Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J Chemother 2000 0.79
108 The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia. J Antimicrob Chemother 1991 0.79
109 [Influence of potassium deficiency on the distribution of lithium ions between the intra- and extracellular space]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1967 0.79
110 [Antimycotic treatment of pulmonary aspergilloma in patients without neutropenia]. Dtsch Med Wochenschr 2002 0.79
111 [S2 guideline for infectious endocarditis]. MMW Fortschr Med 2004 0.79
112 [Antibiotic therapy in cholecystitis, cholangitis and pancreatitis]. Internist (Berl) 2000 0.78
113 Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. Eur J Clin Microbiol Infect Dis 1992 0.78
114 [Lung function studies in young apparently health cigarette smokers versus non-smokers]. Respiration 1972 0.78
115 Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect 2004 0.78
116 Urinary recovery and tolerability of FCE 22101 following single intravenous administration under restricted and high fluid intake. J Antimicrob Chemother 1989 0.78
117 [Biotransformation of selected gyrase inhibitors]. Infection 1986 0.78
118 [Clinical aspects and diagnosis of community-acquired pneumonia]. Dtsch Med Wochenschr 1991 0.78
119 [Community-acquired pneumonia]. Dtsch Med Wochenschr 1989 0.78
120 [The role of antibiotic therapy in infectious enteritis]. Internist (Berl) 2000 0.78
121 [Intestinal tuberculosis: a clinical and diagnostic challenge]. Dtsch Med Wochenschr 2004 0.77
122 [The antibiotic therapy of community-acquired pneumonias]. Dtsch Med Wochenschr 1991 0.77
123 ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. Antimicrob Agents Chemother 2003 0.77
124 Clinical pharmacology of a new ureidopenicillin: Bay K 49999. Chemotherapy 1980 0.77
125 Fibrin degradation product D-dimer in the diagnosis of pulmonary embolism. Klin Wochenschr 1991 0.77
126 In vitro effects of interleukin-10, prednisolone, and GM-CSF on the non-specific immune function of human polymorphonuclear leucocytes and monocytes. Eur J Med Res 2000 0.77
127 [The effect of prednisolone on the resorption of amoxicillin]. Verh Dtsch Ges Inn Med 1978 0.77
128 Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combination. Eur J Clin Microbiol 1982 0.77
129 Simultaneous measurement of collagen type-VI-related antigen and procollagen type-III-N-propeptide levels in bronchoalveolar lavage. Eur Respir J 1994 0.77
130 Pharmacokinetics of loracarbef and interaction with acetylcysteine. Eur J Clin Microbiol Infect Dis 1992 0.77
131 [Effect of doxycycline and isoconazole nitrate on human intestinal fungal flora]. Arzneimittelforschung 1983 0.76
132 Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group. J Antimicrob Chemother 1995 0.76
133 Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother 1995 0.76
134 Expression of adhesion molecules in peripheral pulmonary vessels from smokers and nonsmokers. Lung 1996 0.76
135 Aminoglycoside dosage in hemodialysis patients. J Clin Pharmacol 1987 0.76
136 Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies. Intensive Care Med 2008 0.76
137 Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva. Eur J Clin Pharmacol 1997 0.75
138 Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Antimicrob Agents Chemother 2003 0.75
139 Safety of quinolones. Lancet 1998 0.75
140 Rational approach to the diagnosis of Pneumocystis carinii pneumonia (PCP) Eur Respir J 1993 0.75
141 Re: A. Bauernfeind et al.: Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens (Infection 23 [1995] 316-321) Infection 1996 0.75
142 [Sepsis: a conception in change. Possibilities and limitations of diagnosis based on clinical criteria]. Dtsch Med Wochenschr 1995 0.75
143 [Incompatibility of tuberculosis therapy in a patient with AIDS]. Dtsch Med Wochenschr 1994 0.75
144 [Idiopathic pulmonary fibrosis. III. Case report]. Dtsch Med Wochenschr 2001 0.75
145 Selective decontamination of the digestive tract: indications and problems. Infection 1996 0.75
146 Serum bactericidal activity and kinetics of azlocillin and moxalactam after single and combined administration. J Antimicrob Chemother 1983 0.75
147 [Serologic early diagnosis of pneumonia caused by Mycoplasma pneumoniae]. Dtsch Med Wochenschr 2006 0.75
148 [Randomized comparative study of secondary prevention of Pneumocystis carinii pneumonia in patients with acquired immunologic deficiency syndrome]. Med Klin (Munich) 1990 0.75
149 [Therapy of pulmonary mycoses]. Dtsch Med Wochenschr 1992 0.75
150 [Antibiotic treatment of broncho-pulmonary infections]. Prax Pneumol 1970 0.75
151 [Immunization in pneumology]. Pneumologie 1994 0.75
152 Respiratory infection: the disease. Clin Ther 1985 0.75
153 [Antibacterial therapy in infectious bronchial diseases. Recommendations of the German League for control of respiratory tract diseases]. Med Monatsschr Pharm 1992 0.75
154 [A single dosage of aminoglycosides?]. Dtsch Med Wochenschr 1995 0.75
155 Multivariate analysis of aminoglycoside levels in hemodialysis patients. Chemotherapy 1989 0.75
156 [The diagnosis of nosocomial pneumonia]. Dtsch Med Wochenschr 1997 0.75
157 [Chronic eosinophilic pneumonia]. Dtsch Med Wochenschr 2004 0.75
158 [Therapy of sarcoidosis]. Dtsch Med Wochenschr 1995 0.75
159 [The clinical picture and diagnosis of bronchiectasis]. Dtsch Med Wochenschr 1993 0.75
160 [Pulmonary parasitoses as differential diagnosis of lung tuberculosis]. Z Arztl Fortbild (Jena) 1991 0.75
161 [Resistant lung tuberculosis in Berlin 1987-1993]. Pneumologie 1996 0.75
162 [The clinical significance of penicillin-resistant pneumococci]. Dtsch Med Wochenschr 1993 0.75
163 [Influenza infection and antibiotic therapy]. Dtsch Med Wochenschr 1993 0.75
164 [Sisomycin--comparative pharmacokinetic studies and clinical experiences with a new aminoglycoside antibiotic]. Verh Dtsch Ges Inn Med 1975 0.75
165 [Bacterial endocarditis. Clinical picture, treatment and course in 37 patients (author's transl)]. Dtsch Med Wochenschr 1977 0.75
166 [Clinical significance of infections in geriatric patients in long-term nursing care facilities]. Krankenpfl J 2000 0.75
167 [Indications for and results of antibiotic prophylaxis]. Krankenpfl J 1985 0.75
168 The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations. J Chemother 1997 0.75
169 [Which factors are increasing the nephrotoxicity of aminoglucoside antibiotics?]. Dtsch Med Wochenschr 1986 0.75
170 [Value of serum bactericidal test for the treatment of infection]. Med Klin (Munich) 1992 0.75
171 [Prevention and therapy of bronchial infections. Recommendations of the German Respiratory League of the German Society of Pneumology]. Pneumologie 1998 0.75
172 [Pharmacokinetics and clinical experiences with a new aminoglycoside antibioticum: amikacin]. Verh Dtsch Ges Inn Med 1976 0.75
173 [Bacterial endocarditis: clinical aspects, therapy and course forms in 36 patients]. Verh Dtsch Ges Inn Med 1976 0.75
174 [Infection and septic shock. Antibiotic therapy]. Verh Dtsch Ges Inn Med 1987 0.75
175 [Fluoroquinolones. 1. Their chemical structure, mechanism of action and antibacterial activity]. Dtsch Med Wochenschr 1988 0.75
176 [Diagnosis and therapy of aspiration pneumonia]. Dtsch Med Wochenschr 2006 0.75
177 [Fever of unknown origin in the 21st century: infectious diseases]. Dtsch Med Wochenschr 2005 0.75
178 [Fluoroquinolone. 2. Pharmacokinetics and clinical use]. Dtsch Med Wochenschr 1988 0.75
179 [Use of positron-emission tomography in oncology]. Dtsch Med Wochenschr 1996 0.75
180 [Diagnosis and therapy of abscess forming pneumonia]. Ther Umsch 2001 0.75
181 [Diagnosis of haemoptoe/haemoptysis]. Dtsch Med Wochenschr 2005 0.75
182 [Bronchopulmonary infection in adults. "Banal" infections, primary atypical pneumonia, bacterial pneumonias]. Med Welt 1981 0.75
183 [Progress with management of hereditary angioedema]. MMW Fortschr Med 2013 0.75
184 [Therapy of tuberculosis]. Dtsch Med Wochenschr 1990 0.75
185 [Effects of cephalothin, gentamicin, and their combination on the bacterium Proteus mirabilis]. Int J Clin Pharmacol 1972 0.75
186 [MRSA (methicillin-resistant Staphylococcus aureus) infections in patients with pulmonary diseases]. Pneumologie 1996 0.75
187 [Idiopathic pulmonary fibrosis. I. Diagnosis]. Dtsch Med Wochenschr 2001 0.75
188 [Pneumocystis jiroveci pneumonia in immunocompromised patients without AIDS -- a case series]. Dtsch Med Wochenschr 2006 0.75
189 [Studies on the in vitro effects of cephalothin and gentamicin, alone and in combination, on proteus mirabilis and enterococci (author's transl)]. Infection 1975 0.75
190 [The spectrum of pulmonary manifestations of aspergillosis]. Dtsch Med Wochenschr 1989 0.75
191 [Legionnaires' disease: prospective study of its incidence, clinical features and prognosis. (author's transl)]. Dtsch Med Wochenschr 1982 0.75
192 [Use of antibiotics in medical practice. Round Table]. Verh Dtsch Ges Inn Med 1984 0.75
193 [Venous impurity and chronic intestinal diseases]. Schweiz Med Wochenschr 1971 0.75
194 [Bacterial infections and possibility of oral antibiotic therapy with cephaclor]. Infection 1979 0.75
195 [Systemic antimycotic treatment]. Dtsch Med Wochenschr 1982 0.75
196 [Frequent errors in antibiotic therapy]. Verh Dtsch Ges Inn Med 1989 0.75
197 [Diagnosis of lung abscesses]. Dtsch Med Wochenschr 1996 0.75
198 [The wide spectrum of modern pneumology]. Dtsch Med Wochenschr 2006 0.75
199 [Paget's disease of the spine with partial paraplegia]. Dtsch Med Wochenschr 1969 0.75
200 [Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)]. Infection 1979 0.75
201 [Clinical aspects and prognosis of Legionella infections]. Schriftenr Ver Wasser Boden Lufthyg 1987 0.75
202 [Pneumonia]. Pneumologie 1996 0.75
203 [Activity loss of antibiotics in infusion solutions]. Verh Dtsch Ges Inn Med 1973 0.75
204 [Fever of unknown origin in the 21st century. 2. Non-infectious diseases (autoimmune diseases)]. Dtsch Med Wochenschr 2005 0.75
205 Perioperative antibiotic prophylaxis in bile-duct interventions: results of two prospective randomized studies. Chemotherapy 1987 0.75
206 Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. J Antimicrob Chemother 2007 0.75
207 [Doxycycline pellets: a suitable formulation with guaranteed bioequivalence]. Arzneimittelforschung 1980 0.75
208 [Enzymatic quick determination of aminoglycoside antibiotics in serum]. Int J Clin Pharmacol Biopharm 1976 0.75
209 [Pharmacologic studies or aminoglycoside antibiotics (amikacin, gentamicin, sisomicin, tobramycin)]. Adv Clin Pharmacol 1978 0.75
210 [The effect of oral by administered theophylline on specific airway resistance in airway obstruction]. Arzneimittelforschung 1972 0.75
211 [Clinical results with sulbactam/ampicillin in a multicenter study of 425 patients]. Med Klin (Munich) 1989 0.75
212 [Recent fluoroquinolones. Highly effective weapons for ambulatory therapy]. MMW Fortschr Med 1999 0.75
213 [Diagnosis of tuberculosis]. Dtsch Med Wochenschr 1990 0.75
214 [Pharmacokinetics and clinical observations of sisomicin, a newly developed aminoglycoside derivative (author's transl)]. Dtsch Med Wochenschr 1975 0.75
215 Biliary elimination of apalcillin in cholecystectomized patients. Chemotherapy 1985 0.75
216 Antimicrobial therapy in dialysis patients. II. Remaining antibiotics and antimicrobiologic agents. Blood Purif 1985 0.75
217 Radiolabeled metaiodobenzylguanidine (mibg) in diagnosis and therapy of neuroblastoma - results from basic research (review). Int J Oncol 1995 0.75
218 Kinetic in vitro studies of antibacterial effects of the combination of new penicillins and cefalosporins against Proteus vulgaris. Chemotherapy 1982 0.75
219 [Infections caused by Stenotrophomonas maltophilia (SMA) in intensive care patients--a prospective case-control study]. Dtsch Med Wochenschr 2001 0.75
220 [Tuberculosis in terminal renal insufficiency]. Prax Klin Pneumol 1983 0.75
221 [High-resolution magnetic resonance tomography (HR-MRT) of the pleura and thoracic wall: normal findings and pathological changes]. Rofo 1995 0.75
222 [The influence of laevomepromazine and prometazine on respiration in healthy subjects and patients with pulmonary emphysema]. Arzneimittelforschung 1971 0.75
223 Efficacy of reproterol assessed by the acetylcholine provocation test. Respiration 1979 0.75
224 [Pharmacokinetic aspects of oral therapy with antibiotics]. Internist (Berl) 1982 0.75
225 [Influenza infection and antibiotic therapy]. Dtsch Med Wochenschr 1993 0.75
226 [What is the evidence in the prevention ventilator-associated pneumonia? Evaluation of several controversial prevention measures in connection with ventilation and suction systems]. Dtsch Med Wochenschr 1999 0.75
227 Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers. Eur J Clin Microbiol Infect Dis 2008 0.75
228 [Problems of pharmacotherapy of infections in the aged]. Internist (Berl) 2003 0.75
229 [Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide]. Z Gesamte Inn Med 1991 0.75
230 [Pulmonary complications in acquired immunodeficiency syndrome. Results of a prospective study]. Dtsch Med Wochenschr 1988 0.75
231 [Use of polypropylen disposable syringes in blood-gas laboratory]. Z Prakt Anasth 1971 0.75
232 Hospital-acquired pneumonia in Europe. Eur Respir J 2009 0.75
233 [Indications for and use of home artificial respiration]. Dtsch Med Wochenschr 1994 0.75
234 Increased awareness of aspergillosis in acute leukemia patients. Haematol Blood Transfus 1987 0.75
235 [Value of diagnostic procedures in fiberoptic bronchoscopy of pulmonary infections]. Pneumologie 1990 0.75
236 [Cefoperazone--a new cephalosporin antibiotic with broader spectrum of activity]. Med Klin 1981 0.75
237 Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers. Clin Microbiol Infect 2003 0.75
238 [Endocarditis as an interdisciplinary problem]. Fortschr Med 1984 0.75
239 Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis. Eur J Clin Microbiol Infect Dis 2003 0.75
240 [Oral antibiotic therapy in gastrectomized patients]. Verh Dtsch Ges Inn Med 1973 0.75
241 Oral candidosis and its role in immunocompromised patients. Mycoses 1989 0.75
242 [Pulmonary melioidosis in a German Southeast Asia tourist]. Pneumologie 1997 0.75
243 [The in vitro effects of cephalothin, gentamicin and their combination against Proteus mirabilis and Enterococci]. Adv Clin Pharmacol 1974 0.75
244 [The effect of endoscopic abdominal examinations on respiration]. Respiration 1972 0.75
245 [Bronchoscopic diagnosis of pneumonia]. Z Arztl Fortbild (Jena) 1992 0.75
246 [Pneumococcal vaccination in obstructive lung diseases -- what can we expect?]. Dtsch Med Wochenschr 2005 0.75
247 [Gram-negative nosocomial infections. Epidemiology, causative agents, clinical aspects, trends]. Schweiz Rundsch Med Prax 1983 0.75
248 Pharmacokinetics and antibacterial efficacy in vivo of beta-lactam combinations against Proteus vulgaris. Chemotherapy 1982 0.75
249 [The clinical picture and diagnosis of pulmonary mycoses]. Dtsch Med Wochenschr 1992 0.75
250 [Status of infectiology in Germany]. Dtsch Med Wochenschr 2001 0.75
251 [Inpatient treatment costs of exacerbated chronic obstructive lung disease]. Pneumologie 1999 0.75
252 [Therapy of urogenital tuberculosis]. Dtsch Med Wochenschr 1992 0.75
253 [Pneumology -- epidemiological changes and structural consequences]. Dtsch Med Wochenschr 2005 0.75
254 [Respiratory filters and pneumonia: many unresolved questions]. Dtsch Med Wochenschr 2001 0.75
255 [The new pneumonias]. Verh Dtsch Ges Inn Med 1981 0.75
256 [The therapy of bronchiectasis]. Dtsch Med Wochenschr 1993 0.75
257 Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy. Eur Respir J 2001 0.75
258 [Intermittent nasal positive pressure ventilation with a ventilator in accordance with the Medical Device Regulation III (MedGV III). Clinical experiences with the BREAS PV 201 in 19 patients]. Pneumologie 1996 0.75
259 [Invasive and non-invasive home ventilation--changes between 1982 and 1996]. Med Klin (Munich) 1999 0.75
260 [Generalized so-called idiopathic amyloidosis. Clinical and pathologic-anatomical aspects]. Dtsch Med Wochenschr 1972 0.75
261 Comparative pharmacokinetics and clinical experience with a new cephalosporin-derivative: cefazolin. Chemotherapy 1975 0.75
262 Cefotaxime: efficacy and tolerance in lower respiratory tract infections caused by gram-positive cocci. Infection 1985 0.75
263 [New understanding in the study of infectious diseases. Report of the 25th Ludwig Heilmeyer Symposium of the Society for the Advancement of Internal Medicine]. Dtsch Med Wochenschr 1999 0.75
264 [Prophylaxis and therapy of bronchial infections. Recommendations of the German Airway League of the German Pulmonology Association]. Med Klin (Munich) 1997 0.75
265 Differences between American and German medical students and physicians in knowledge of infectious diseases. Eur J Clin Microbiol Infect Dis 2000 0.75
266 Determination of a new cephalosporin, SCE-2787, in serum and urine by high-performance liquid chromatography. J Chromatogr 1993 0.75
267 [Therapy of bronchopulmonary infections in adults]. Krankenpfl J 1982 0.75
268 Development of pleural and pericardial effusions during itraconazole therapy of pulmonary aspergillosis. Eur J Clin Microbiol Infect Dis 1993 0.75
269 [Clinical and prognostic aspects of nosocomial Legionnaires pneumonias]. Prax Klin Pneumol 1983 0.75
270 [Diagnosis of sarcoidosis]. Dtsch Med Wochenschr 1995 0.75
271 Combination effects of ciprofloxacin, clindamycin, and metronidazole intravenously in volunteers. Am J Med 1989 0.75
272 Pulmonary schistosomiasis resembling acute pulmonary tuberculosis. Eur Respir J 1991 0.75
273 [A multi-centre study of reproterol, a bronchodilator (author's transl)]. Dtsch Med Wochenschr 1977 0.75
274 [Ambulant atypical pneumonia: clinical diagnosis and therapy]. Immun Infekt 1992 0.75
275 [Clinical pharmacology of three ampicillins and amoxicillin by oral application]. Adv Clin Pharmacol 1974 0.75
276 [Pharmacokinetics and clinical experience with 2 new penicillins: azlocillin and mezlocillin]. Verh Dtsch Ges Inn Med 1978 0.75
277 [Diagnosis of pulmonary infections]. Internist (Berl) 1995 0.75
278 [Changes in the spectrum of the causative agents of community-acquired pneumonias (1982-1992)]. Dtsch Med Wochenschr 1997 0.75
279 [Clinical picture of Legionnaires' disease (author's transl)]. Infection 1982 0.75
280 [Pharmacokinetics and therapeutic experiences with a new cephalosporin derivative: cefazoline]. Verh Dtsch Ges Inn Med 1974 0.75
281 [Indications for the monitoring of aminoglycoside serum concentrations in internal medicine (author's transl)]. Infection 1977 0.75
282 Renal elimination of sulfo-ciprofloxacin, a new metabolite of ciprofloxacin. Eur J Clin Microbiol 1986 0.75
283 [Antibiotic therapy in kidney failure]. Med Welt 1983 0.75
284 [Bacterial pneumonias]. Internist (Berl) 1985 0.75
285 [Theme issue pneumology]. Dtsch Med Wochenschr 2000 0.75
286 [Infection from the viewpoint of the infectiologist]. Beitr Infusionther Klin Ernahr 1983 0.75
287 [Infection 1979 to 1986. Epidemiology, etiology, clinical aspects and prognosis in 691 patients]. Med Klin (Munich) 1989 0.75
288 [Antimycotic therapy on intensive care units: contra]. Anasthesiol Intensivmed Notfallmed Schmerzther 1993 0.75
289 [Influence of abdominal endoscopic examinations on respiration]. Verh Dtsch Ges Inn Med 1971 0.75
290 The role of 13-hydroxylinoleic acid in the activation of macrophages by lipopolysaccharide. Adv Exp Med Biol 1990 0.75
291 [Complex choices in respiratory tract infections: the search for simple solutions]. Med Mal Infect 2007 0.75
292 [Pharmacokinetics and clinical experience with amikacin. A new aminoglycoside antibiotic]. Dtsch Med Wochenschr 1976 0.75
293 [Therapy of lung abscesses]. Dtsch Med Wochenschr 1996 0.75
294 [BiPAP therapy of respiratory disorders in patients with congenital neuromuscular diseases]. Med Klin (Munich) 1995 0.75